
WilmerHale Advises Underwriters in Follow-on Public Offering of Milestone Pharmaceuticals Inc.

MARCH 15, 2024

WilmerHale represented the underwriters in the follow-on public offering of 19,666,667 common shares and 3,333,333 pre-funded warrants to purchase common shares of Milestone Pharmaceuticals Inc., a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. The common shares were issued at a public offering price of \$1.50 per share and the pre-funded warrants had a public offering price of \$1.499 per pre-funded warrant. The gross proceeds to Milestone were \$34.5 million, before deducting underwriting discounts, commissions and offering expenses. The offering closed on March 4, 2024.

The WilmerHale team consisted of [Lisa Firenze](#), [Ryan Brewer](#) and [Molly Nelson](#), with assistance from [Bruce Manheim](#), [Barish Ozdamar](#) and [Meghan Walsh](#).